Docoh
Loading...

ECIA Encision

Encision, Inc. is a medical device company. The firm is engaged in the designing, developing and manufacturing of patented surgical instruments in the United States. Its patented Active Electrode Monitoring technology provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The company was founded by Vern D. Kornelsen, David W. Newton, and Roger C. Odell on February 1, 1991 and is headquartered in Boulder, CO.

Company profile

Ticker
ECIA
Exchange
CEO
Gregory J. Trudel
Employees
Incorporated
Location
Fiscal year end
Former names
ELECTROSCOPE INC
SEC CIK
IRS number
841162056

ECIA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

23 Jun 21
24 Jun 21
31 Mar 22
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 21 Mar 20 Mar 19 Mar 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Encision earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.47M 1.47M 1.47M 1.47M 1.47M 1.47M
Cash burn (monthly) (positive/no burn) (positive/no burn) (positive/no burn) 5.14K (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a n/a 14.32K n/a n/a
Cash remaining n/a n/a n/a 1.46M n/a n/a
Runway (months of cash) n/a n/a n/a 284.2 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Aug 20 Fries Robert H common stock Buy Aquire P No No 0.47 40,000 18.8K 540,000
13 Aug 20 Fries Robert H common stock Buy Aquire P No No 0.55 2,089 1.15K 500,000
13 Aug 20 Fries Robert H common stock Buy Aquire P No No 0.54 37,911 20.47K 497,911
12 Aug 20 Mala M Ray Common stock option-right to buy Common Stock Grant Aquire A No No 0.5 10,000 5K 10,000
12 Aug 20 Gregory J. Trudel Common stock option-right to buy common stock Grant Aquire A No No 0.5 10,000 5K 10,000
12 Aug 20 David W Newton Common stock option-right to buy common stock Grant Aquire A No No 0.5 10,000 5K 10,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

8.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 1 EXIT
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 424K 424K
Total shares 985K 985K
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
DAFNA Capital Management 985K $424K 0.0%
Largest transactions
Shares Bought/sold Change
DAFNA Capital Management 985K 0 0.0%

Financial report summary

?
Competition
MedtronicMedtronic
Management Discussion
  • Net Product revenue. Net product revenue for the fiscal year ended March 31, 2021 (“FY 21”) was $7,010,657, and for the fiscal year ended March 31, 2020 (“FY 20”), net revenue was $7,670,206, a decrease of 9%. The decrease of AEM product net revenue is attributable to business lost from hospitals that used AEM technology during the year. Product revenue for the fiscal year ended March 31, 2021 decreased primarily as a result of the decrease in non-essential surgical procedures performed during this period due to the COVID-19 pandemic.
  • Net Service revenue. Net service revenue for FY 21 was $527,177, and for FY 20 net revenue was none. Net service revenue was for engineering services performed under a Master Services Agreement with Auris Health, Inc. (“Auris Health”). Auris Health is a part of the Johnson & Johnson family of companies. Under the agreement, we will collaborate on the integration of AEM technology into monopolar instrumentation produced by Auris Health for advanced surgical applications. The engineering services are ongoing. We have substantially completed Phase 1 of the project and Phase 2 was started.
  • Gross profit. Gross profit in FY 21 was $3,905,103, which represented a decrease of $98,513, or 2%, from gross profit in FY 20 of $4,003,616. Gross profit margin was 52% of net revenue for FY 21 and FY 20. Gross profit decreased in FY 21 from FY 20 due to lower net product revenue that was partially offset by higher net service revenue.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: accuracy, alter, annum, arising, attack, billed, breach, canceled, cancelled, category, CECL, cold, corroborate, cutoff, default, destroyed, Disaster, discontinued, disease, disruption, economy, EIDL, enTouch, evidenced, extinguishment, family, feasible, forecast, fraudulently, hot, indemnity, intrusion, judgment, lender, long, malfeasance, mandated, methodology, misuse, moving, outcome, pandemic, perfectly, persistent, phishing, prepaid, properly, qualitative, refund, reputation, resolution, salability, SBA, simple, skill, spread, stolen, storage, superior, tariff, theft, thermochromic, thirty, traditional, trajectory, transmission, uncollectible, user, waste
Removed: collection, comparability, deposited, disclosing, exporting, importing, leasing, passed, recently, recognizing, repay, RSU, ship, title, transparency